|
James F. Young, Ph.D. has over 20 years of experience in the fields of molecular genetics, microbiology, immunology and pharmaceutical development. In December 2000, Dr. Young was promoted to the position of president, research and development. He joined MedImmune in 1989 as vice president, research and development. In 1995, he was promoted to senior vice president and in 1999 he was promoted to executive vice president, research and development. Throughout this period he has overseen the preclinical development of all products in MedImmune's pipeline, including the company's flagship product, Synagis®, which is the first and still the only monoclonal antibody approved for an infectious disease. Prior to MedImmune, from 1983 to 1989, Dr. Young was instrumental in building the department of molecular genetics at Smith Kline & French Laboratories culminating in the position of Director, Department of Molecular Genetics. From 1978 to 1983, he was on the faculty of the department of microbiology at Mount Sinai School of Medicine in New York, NY. Dr. Young received his doctorate in microbiology and immunology from Baylor College of Medicine in Houston, Texas and Bachelor of Science degrees in biology and general science from Villanova University in Villanova, Pennsylvania.
| 